Enhancing Rehabilitation After Stroke (Enhance)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00868010|
Recruitment Status : Unknown
Verified March 2013 by Ellen Whyte, University of Pittsburgh.
Recruitment status was: Recruiting
First Posted : March 24, 2009
Last Update Posted : March 5, 2013
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke||Drug: donepezil Drug: placebo||Phase 3|
Stroke is a leading cause of disability in the US (Thom 2006). The total number of stroke survivors (currently estimated as 5.5 million Americans) will continue to increase as the population ages and as the medical management of acute stroke continues to improve. Given stroke's devastating impact on activities of daily living and the large numbers of Americans afflicted, improving acute medical rehabilitation outcomes after stroke is of great public health importance.
Predictors of poor functional recovery post-stroke include impairments in cognition and motivation. Recent evidence indicates that acetylcholinesterase inhibitors may improve cognition and motivation; hence, their use post-stroke may lead to improved rehabilitation outcomes. Our group has demonstrated that use of the acetylcholinesterase inhibitor donepezil is associated with improved functional recovery in a pilot sample (n = 40) of elderly, cognitively impaired stroke survivors undergoing inpatient rehabilitation. Specifically, in this 12 week open-label study, those subjects receiving donepezil experienced a clinically meaningful 14 point greater improvement on the Functional Independence Measure (FIM) than an archival comparator group.
Based on these promising pilot study results, we propose a 12-week randomized, double-blind, placebo-controlled trial (followed by a 12 week off-drug observation period) in order to test the efficacy of donepezil to promote post-stroke functional recovery in older, cognitively impaired stroke survivors undergoing inpatient rehabilitation. We will also use this randomized controlled trial to examine the drug's effect on cognition post-stroke; specifically, the drug's effect on those cognitive domains (attention/working memory, information psychomotor speed, and episodic memory) that are relevant to functional outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Donepezil to Promote Functional Recovery Post-stroke|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||August 2013|
|Estimated Study Completion Date :||November 2013|
Experimental: 1: donepezil
Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
Other Name: Aricept
Placebo Comparator: 2. placebo
Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
- Functional Independence Measure (FIM) [ Time Frame: Weekly/12 weeks ]
- Cognitive Function (ImPACT battery used to assess attention - working memory continuum, information processing speed, and verbal and visual episodic memory.) [ Time Frame: Multiple time points over 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00868010
|Contact: Kara Kentonemail@example.com|
|United States, Ohio|
|Hillside Rehabilitation Hospital||Not yet recruiting|
|Warren, Ohio, United States, 44484|
|Contact: Nancy Landgraff, PhD 330-941-2703 firstname.lastname@example.org|
|Principal Investigator: Nancy Landgraff, PhD|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15213|
|Contact: Kara Kenton 412-246-5815 email@example.com|
|Sub-Investigator: Howard Aizenstein, MD, PhD|
|Principal Investigator: Ellen M Whyte, MD|
|Sub-Investigator: Meryl Butters, PhD|
|Sub-Investigator: Ariel Gildengers, MD|
|Sub-Investigator: Jordan Karp, MD|
|Sub-Investigator: Oscar Lopez, MD|
|Sub-Investigator: Sati Mazumdar, MD|
|Sub-Investigator: Michael Munin, MD|
|Sub-Investigator: Charles Reynolds, MD|
|Sub-Investigator: Elizabeth Skidmore, PhD|
|Principal Investigator:||Ellen M Whyte, MD||University of Pittsburgh|